Last reviewed · How we verify
Hydroxyethylstarch 130/0,4
Hydroxyethylstarch 130/0,4 is a Synthetic colloid volume expander Small molecule drug developed by Rigshospitalet, Denmark. It is currently FDA-approved for Acute blood loss and hypovolemia requiring volume replacement in perioperative and critical care settings.
Hydroxyethylstarch (HES) 130/0.4 is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and fluid retention in the bloodstream.
Hydroxyethylstarch 130/0.4 is a type of colloid solution used in medical settings. It is not a small molecule, as per ChEMBL, but its exact modality is not specified in the provided facts.
At a glance
| Generic name | Hydroxyethylstarch 130/0,4 |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Synthetic colloid volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
HES 130/0.4 is a third-generation synthetic colloid composed of hydroxyethyl-substituted amylopectin with a mean molecular weight of 130 kDa and degree of substitution of 0.4. It functions as a volume expander by remaining in the intravascular space longer than crystalloids, thereby maintaining oncotic pressure and improving hemodynamic stability. The notation 130/0.4 indicates its molecular weight and substitution ratio, which influence its pharmacokinetic profile and clinical efficacy.
Approved indications
- Acute blood loss and hypovolemia requiring volume replacement in perioperative and critical care settings
Common side effects
- Acute kidney injury
- Coagulopathy / increased bleeding
- Hyperchloremic acidosis
- Anaphylaxis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxyethylstarch 130/0,4 CI brief — competitive landscape report
- Hydroxyethylstarch 130/0,4 updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI
Frequently asked questions about Hydroxyethylstarch 130/0,4
What is Hydroxyethylstarch 130/0,4?
How does Hydroxyethylstarch 130/0,4 work?
What is Hydroxyethylstarch 130/0,4 used for?
Who makes Hydroxyethylstarch 130/0,4?
What drug class is Hydroxyethylstarch 130/0,4 in?
What development phase is Hydroxyethylstarch 130/0,4 in?
What are the side effects of Hydroxyethylstarch 130/0,4?
Related
- Drug class: All Synthetic colloid volume expander drugs
- Manufacturer: Rigshospitalet, Denmark — full pipeline
- Therapeutic area: All drugs in Critical Care / Anesthesia
- Indication: Drugs for Acute blood loss and hypovolemia requiring volume replacement in perioperative and critical care settings
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing